




## Bendamustine

Revised: July 19, 2021.

CASRN: 16506-27-7



## Drug Levels and Effects

### Summary of Use during Lactation

No information is available on the use of bendamustine during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, especially alkylating agents such as bendamustine.[1] Based on the half-life of the drug and its metabolites, the drug should be eliminated from the milk by 24 to 48 hours after the last dose. The manufacturer recommends that breastfeeding be discontinued during bendamustine therapy and for at least 1 week after the last dose.

### Drug Levels

*Maternal Levels.* Relevant published information was not found as of the revision date.

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

**Attribution Statement:** LactMed is a registered trademark of the U.S. Department of Health and Human Services.

*Infant Levels.* Relevant published information was not found as of the revision date.

## Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

## Effects on Lactation and Breastmilk

Some evidence indicates that the closely related drug carmustine can increase serum prolactin.[2]

## References

1. Pistilli B, Bellettini G, Giovannetti E, et al. Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: How should we counsel cancer patients about breastfeeding? *Cancer Treat Rev.* 2013;39:207–11. PubMed PMID: 23199900.
2. Constine LS, Rubin P, Woolf PD, et al. Hyperprolactinemia and hypothyroidism following cytotoxic therapy for central nervous system malignancies. *J Clin Oncol.* 1987;5:1841–51. PubMed PMID: 3681371.

## Substance Identification

### Substance Name

Bendamustine

### CAS Registry Number

16506-27-7

### Drug Class

Breast Feeding

Lactation

Antineoplastic Agents, Alkylating

Nitrosourea Compounds